Logo

High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  1. Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  2. Department of Rheumatology, Clinical Immunology and Allergy, Medical School, University of Crete, Heraklion, Greece.
  3. Department of Rheumatology, Clinical Immunology and Allergy, Medical School, University of Crete, Heraklion, Greece.
  4. Joint Rheumatology Program, First Department of Propaedeutic and Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  5. Joint Rheumatology Program, First Department of Propaedeutic and Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  6. Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  7. Rheumatology Clinic, Medical School, University of Ioannina, Ioannina, Greece.
  8. Rheumatology Clinic, Medical School, University of Ioannina, Ioannina, Greece.
  9. Rheumatology Clinic, Medical School, University of Ioannina, Ioannina, Greece.
  10. Department of Medical Affairs, MSD, Greece.
  11. Department of Rheumatology, Clinical Immunology and Allergy, Medical School, University of Crete, Heraklion, Greece.
  12. Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. dvassilop@med.uoa.gr

CER10497 Submission on line
2018 Vol.36, N°2 - PI 0254, PF 0262
Full Papers

Rheumatology Article
Rheumatology Article

 

Abstract

OBJECTIVES:
Our primary objective was to study the long-term survival on drug (SOD) of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) treated with golimumab (GLM) in real life settings.
METHODS:
This was a retrospective, observational study of all patients treated with GLM in 4 Academic Centres in Greece during a 4-year period (09/2010-06/2014). SOD was analysed using Kaplan-Meier survival analysis, while Cox regression analysis estimating hazard ratios (HRs) for different baseline variables associated with drug discontinuation was performed for each disease.
RESULTS:
328 patients (RA: 166, PsA: 82, AS: 80) were included. The estimated SOD at 2 and 3 years was 68% and 62% overall and was better for AS (79% and 76%) compared to RA (69% and 60%, p=0.067) and PsA (58% and 53%, p=0.001) patients; no difference was noted between RA and PsA patients (p=0.204). There was no difference in SOD between biologic-naïve and experienced nor between non-biologic co-treated or GLM monotherapy treated patients. Seropositivity (rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies) was associated with a lower risk for GLM discontinuation by multivariate analysis (HR=0.5, 95% CI=0.0.25–1.1, p=0.05) in RA patients. During 606 patient-years of follow-up, 11 (3.3%) patients discontinued GLM due to adverse events (AE), accounting for 11% of treatment discontinuations. The rates of serious AEs and serious infections were 2.3 and 1.0/100-patient-years, respectively.
CONCLUSIONS:
In this real-life study, GLM showed a high 3-year SOD in patients with inflammatory arthritides with a low rate of discontinuation due to AEs.

PMID: 29148406 [PubMed]

Received: 10/04/2017 - Accepted : 24/07/2017 - In Press: 09/11/2017 - Published: 18/04/2018